Expert Interview
Discussing FcRn and CD19 as a target in primary immune thrombocytopenia (ITP)
Ticker(s): ARGX, AMGN, ELYMInstitution: Georgetown/Medstar Health
- Associate Professor at Georgetown's Lombardi Cancer Center's department of medicine.
- Board-certified in internal medicine, hematology, and medical oncology.
- Participates in clinical trials for a variety of diseases including ITP, autoimmune hemolytic anemia, cold agglutinin disease, and hemophagocytic lymphohistiocytosis.
Roughly how many patients with ITP do you currently manage?
Added By: c_adminWhat are the mechanisms of action and effectiveness of FcRn, CD38, and CD19 in treating immune thrombocytopenia (ITP), and how do these therapies compare, especially in relation to rituximab and its long-term efficacy?
Can you explain why rituximab may lose effectiveness over time in some ITP patients, and how the evolution of ITP from B-cell to T-cell mediated processes might affect treatment outcomes?
How do the response rates and effectiveness of different FcRn administration methods (IV vs. SubQ) compare, and what could explain the variance in efficacy between these methods?
What are the implications of CD19 CAR-T therapy in ITP, particularly in terms of immune system reset and potential side effects, and how does this approach compare to targeting plasma cells with anti-CD38 therapy?
Added By: catalin_adminAre there any promising new therapies or ongoing clinical trials in ITP, particularly those targeting B-cell signaling pathways, and how might they contribute to better long-term outcomes for patients?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
